Skip to main content
. Author manuscript; available in PMC: 2018 Jan 17.
Published in final edited form as: Cell Rep. 2017 Dec 26;21(13):3672–3680. doi: 10.1016/j.celrep.2017.12.014

Figure 3. NP-Ficoll Treatment Shifts OVA+ GC B Cell Population to DZ.

Figure 3

Mice were immunized and treated as in Figure 2A.

(A) Gating strategy for total T follicular or Tfr cells (CD4+, CD19−, CXCR5hi, PD1hi and CD4+, CD19−, CXCR5hi, PD1hi, Foxp3−/+).

(B and C) Quantification of T follicular (B) and Tfr cells (C).

(D) Ratio of T follicular to GC B cell after NP-Ficoll treatment on day 9.

(E and F) Representative OVA-specific GC dark zone (DZ) gate (B220+, GL7+, CD4−, CD38lo, OVA+, CxCr4hi, CD86lo) (E) and quantification (F) on day 9.

(G and H) Representative staining intensity of pS6 (G) and quantification (H).

Bars represent mean; NS, not significant; *p < 0.05, **p < 0.01, unpaired Welch’s t test. See also Figure S3.